PHVS Stock Summary and Trading Ideas (Pharvaris N.V. - | NASDAQ:PHVS)

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Pharvaris N.V. - trades on the NASDAQ stock market under the symbol PHVS.

As of July 31, 2026, PHVS stock price declined to $32.62 with 498,548 million shares trading.

PHVS has a beta of 0.87, meaning it tends to be less sensitive to market movements. PHVS has a correlation of 0.06 to the broad based SPY ETF.

PHVS has a market cap of $2.28 billion. This is considered a Mid Cap stock.

In the last 3 years, PHVS traded as high as $36.60 and as low as $11.51.

The top ETF exchange traded funds that PHVS belongs to (by Net Assets): IBB, IEFA, SCZ, EWN, ONEQ.

PHVS has outperformed the market in the last year with a return of +64.8%, while the SPY ETF gained +18.9%. In the last 3 month period, PHVS beat the market returning +5.2%, while SPY returned +4.2%. However, in the most recent 2 weeks PHVS has underperformed the stock market by returning -3.1%, while SPY returned -0.5%.

PHVS support price is $32.87 and resistance is $34.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PHVS shares will trade within this expected range on the day.